Cure My Disease

Don't miss your cure!

 Log in / Sign up

New prostate cancer combo aims to shrink tumors and lower PSA

NCT ID NCT07407283

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new drug called SHR-4394 combined with other anti-cancer treatments for men with prostate cancer. The goal is to find the safest dose and see if the combination can lower PSA levels, a key marker of prostate cancer. About 100 men aged 18 to 85 will take part. The study is currently recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Second Hospital of Tianjin Medical University

    RECRUITING

    Tianjin, Tianjin Municipality, 300211, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • West China Hospital of Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610041, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.